Article Text

Download PDFPDF

PS2:30 Systemic lupus erythematosus patients with positives autoantibodies with remission or low activity exhibit both lower interferon alpha and interleukin-10 levels
  1. E Grau1,
  2. M Fernandez Matilla2,
  3. FM Ortiz Sanjuan1,
  4. CM Feced Olmos1,
  5. E Labrador Sanchez1,
  6. N Fernandez-Llanio Cornella2,
  7. I Chalmeta Verdejo1,
  8. K Arevalo Ruales1,
  9. R Negueroles Albuixech1,
  10. J Ivorra Cortes1,
  11. JJ Fragio Gil1,
  12. I Martinez Cordellat1,
  13. R Gonzalez Mazario1,
  14. L Gonzalez Puig1,
  15. C Alcañiz Escandell1,
  16. C Najera Herranz1,
  17. I Canovas Olmos1,
  18. E Vicens Bernabeu1,
  19. JE Oller Rodriguez1,
  20. M de la Rubia Navarro1,
  21. JA Castellano Cuesta2,
  22. V Fornes Ferrer3,
  23. D Hervas Marin3 and
  24. JA Roman Ivorra1
  1. 1Rheumatology Department. HUP La Fe, Valencia, Spain
  2. 2Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain
  3. 3Biostatistics Unit. IIS La Fe, Valencia, Spain


Purpose The aim of this study is to assess the clinical and molecular differences in SLE patients with positives autoantibodies and with low clinical activity or in clinical remission compared to the group with clinical activity.

Methods A cross-sectional, observational study of patients diagnosed of SLE according to SLICC 2012 criteria was performed. In these patients a complete blood-test was made, and clinical data by personal interview was collected. We analysed the serum concentration of IL10, BLyS and INF1A by colorimetric methods. Biostatistical analysis was performed with R 3.3.2.

Results We selected 130 SLE patients with serological manifestations (defined by RELESSER study) out of 142 SLE patients. 91 cases showed low activity or remission (SLEDAI <6) and 39 presented moderate or high activity (SLEDAI >6).

SLE patients with positives autoantibodies without clinical activity showed significantly lower anti-dsDNA levels (p=0.006), lower complement consumption (p=0.003) and lower accumulated damage evaluated by SLICC score (p=0.041). No differences on time of evolution in both groups were observed.

In addition, SLE patients with positives autoantibodies without clinical activity exhibit significantly lower levels of IL10 (p<0.001) and INF1A (p=0.019). No differences on BLyS levels in both groups were observed.

Finally, SLE patients with positives autoantibodies with clinical activity present more mucocutaneous lesions (p=0.014), musculoskeletal manifestations (p=0.004), neuropsychiatric manifestations (p=0.002), renal manifestations (p<0.001) and lymphopenia (p=0.008) than patients with positives autoantibodies and without clinical activity.

Conclusion In our series of SLE patients with both serological manifestations and low clinical activity have lower levels of IL10 and INF1A, compared to patients with high clinical activity. This result would suggest that differences in the cytokine levels are not related to autoantibodies presence but there are other mechanisms involved in cytokine production that would also be involved in maintenance of clinical remission.

  • Remission
  • Interpheron Alpha
  • Interleukin-10

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.